Programmatic Areas
In 2018, the Institute for Drug Discovery began forming multi-PI teams to establish and advance drug discovery projects.
The Institute for Drug Discovery has funded the following project teams:
2023 - 2024 Funded Teams
| Lead PI | Co-Pi's | Project Description |
| Xiaoping Bao | Bumsoo Han, Zhong-Yin Zhang | Tissue-on-a-chip for drug discovery and development |
2021 - 2023 Funded Teams
| Lead PI | Co-Pi's | Project Description |
| Yoon Yeo | Bumsoo Han | Systemic delivery of RNA by Nanosac for Alzheimer’s disease therapy |
| Dan Flaherty | Chittaranjan Das, Michael Wendt, Chang-Deng Hu | Development of covalent inhibitors of UCHL1 and UCHL3 for cancer drug discovery |
| Doug LaCount | Richard Kuhn, Betsy Parkinson | The seeds of destruction: Identification of dominant interfering SARS-CoV-2 peptides for the development of new antiviral drugs |
| Rong Huang | Chongli Yuan, Yang Yang | Targeting disease-associated DNMT1 mutations to treat dementias |
| Peristera Paschou | Chris Rochet | Identifying Drug Targets and Biomarkers for Alzheimer’s Disease and Related Dementias |
2018 - 2019 Funded Teams
| Lead PI | Co-Pi's | Project Description |
| Casey Krusemark | Mingji Dai, Markus Lill, Zhong-Yin Zhang | DNA-encoded, drug-like libraries based on privileged scaffolds generated by novel chemistry |
| Tony Hazbun | Mohamed Seleem, Dan Flaherty | Interdisciplinary program in antimicrobial drug discovery using repurposed small molecule drugs |
| Daisuke Kihara | Wen Jiang, Chang-Deng Hu | Deep neural network‐assisted protein structure modeling for drug development from low resolution 3D cryo‐electron microscopy maps |
| Richard van Rijn | Amy Brewster, Markus Lill, Dan Flaherty | β-arrestin 1 - a novel target for seizure disorders |
| Seung-Oe Lim | Michael Wendt, Zhong-Yin Zhang | A new strategy of immunotherapy by combining Src homology domain-containing phosphatase 2 inhibition and immune checkpoint blockade |
| Greg Hockerman |
Casey Krusemark, Yang Yang |
Discovery of subtype-selective ion channel inhibitors targeting extracellular toxin binding domains |
| Tiffany Lyle | Sophie Lelievre, Greg Knipp, Chris Rochet | Development of a novel BBB-on-a-chip model to improve selection of therapeutics |
| Bumsoo Han | Yoon Yeo, Tonglei Li, George Chiu | Program of precision pharmaceutics for precision medicines |
| Herman Sintim | Andy Mesecar, Gaurav Chopra, Greg Knipp, Bennett Elzey | New inhibitors against cancers harboring secondary kinase mutations |